Ocuphire Pharma, Inc. announced that it has entered into common stock purchase agreement with new investor Lincoln Park Capital Fund, LLC, a fund managed by Lincoln Park Capital, LLC to issue common shares for the gross proceeds of $50,000,000 on August 10, 2023. Upon the execution of the Purchase Agreement, the Company issued 246,792 shares of common stock to Lincoln Park and paid Lincoln Park $40,000, which together represents the fee for Lincoln Park?s commitment to purchase shares of the Company?s common stock under the Purchase Agreement. The investor can purchase up to $50,000,000 common shares over a 30-month period at prices per share as computed under the Purchase Agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.79 USD | +6.23% | +6.55% | -40.53% |
May. 10 | Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.53% | 43.15M | |
+34.35% | 693B | |
+29.39% | 584B | |
-3.49% | 372B | |
+20.15% | 332B | |
+6.19% | 294B | |
+14.11% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+9.21% | 168B |
- Stock Market
- Equities
- OCUP Stock
- News Ocuphire Pharma, Inc.
- Ocuphire Pharma, Inc. announced that it expects to receive $50 million in funding from Lincoln Park Capital, LLC